–Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” – –...
–Topline efficacy data expected in Q4 2023 – – Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024...
The two companies also shared next steps in their drug testing regimens. The post Atai, Cybin Give Positive Psychedelic Drug Study Updates appeared first...
The study found that 100 per cent of patients were responsive and 92 per cent went into remission The post Antidepressants enhance DMT efficacy in patients...
The DMT drug appeared more effective when combined with SSRIs. The post Small Pharma Sees Promise Pairing DMT Drug with Antidepressants appeared first...
Topline results from Small Pharma's Phase Ib study exploring the interaction between SSRIs and SPL026, the company’s DMT drug. The post Positive Data...
Efficacy Chart Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy • Results...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...